November 11, 2022

Gilead Genesis Program Supports Research imed.ULisboa

The Gilead Génese program distinguishes several research projects in areas of oncology, such as breast cancer, and virology such as chronic viral hepatitis, HIV/AIDS and Covid-19, and the trophy delivery ceremony took place yesterday, November 8, at Champalimaud Foundation.

Inês Bártolo, a researcher at the Medicine Research Institute of the Faculty of Pharmacy of the University of Lisbon (iMed.Ulisboa), saw her work on spiro-β-lactam compounds, broad-spectrum antivirals, with the potential to fight various pathogens such as the parasite of malaria, HIV and influenza viruses. The development of broad-based antiviral drugs may enable the emergence of diseases resistant by increasing and re-emerging threats and spectra by viruses and antiviral agents with RNA treatments.

This project develop and characterize a new integrated-β-specific against the main complementary RNA viruses (influenza virus, complementary syncytial virus and SARS-CoV-activity-2) in different systems, including mice, and their mechanism of action. The aim is to develop the first spiro-β-lactam antiviral agent for target RNA viruses.

Share on facebook
Share on twitter
Share on linkedin
Back To Top
Come meet us at

Faculdade de Farmácia da Universidade de Lisboa | Av. Professor Gama Pinto
1649-003 Lisboa | Portugal

Phone | +351 217 946 400
Fax | +351 217 946 470
Web |
Email |